Of note, mEHT can directly reduce PARP expression both in OVCAR-3, a high grade serous ovarian adenocarcinoma cell line carrying homozygous TP53 p.Arg248Gln (c.743G > A) mutation [43], and in U87-MG and A172 human glioma cells of wild type TP53 [29,37]. Here, TP53 is linked to glioma.